Cashu
CorMedix Reports Strong Q4 Earnings, Focuses on Innovation and Future Growth Strategies
10 days ago
Stocks
Health Care
crmd
CorMedix
NASDAQ: CRMD
+0.09 (+1.40%)
6.54
USD
At close at Mar 16, 20:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
515.28M
Dividend Yield
0.00%
P/E Ratio
3.16
EPS
-0.31
Revenue
43.47M
Avg. Volume
1.55M
About
What does CRMD do?
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.